Symptoms and General Pathology

All Conditions

Musculoskeletal Diseases

Skin and Connective Tissue Diseases

Immune System Diseases

Inflammation

Necrosis

Arthritis

Arthritis, Rheumatoid

Hypersensitivity

Joint Diseases

Rheumatic Diseases

Collagen Diseases

Connective Tissue Diseases

Autoimmune Diseases

All Drugs and Chemicals

Antineoplastic Agents

Antirheumatic Agents

Dermatologic Agents

Reproductive Control Agents

Anti-Inflammatory Agents

Analgesics

Gastrointestinal Agents

Fluorodeoxyglucose F18

Methotrexate

Tumor Necrosis Factor Inhibitors

Etanercept

Anti-Inflammatory Agents, Non-Steroidal

Analgesics, Non-Narcotic

Immunosuppressive Agents

Immunologic Factors

Patients already taking Methotrexate prior to the study will continue taking 15 mg weekly and start Etanercept 50 mg every week for 16 weeks

Etanercept is a tumor necrosis factor antagonist

etanercept

Boulos Haraoui, MD

The primary goal of this preliminary project is to study the effect of etanercept, a medicine approved by Health Canada for the treatment of rheumatoid arthritis, on the inflammation of certain blood vessels. In particular, the inflammation of the aorta and the carotid arteries will be studied.

This study's goal is to determine if etanercept (that blocks TNF (tissue necrosis factor) alpha) could have an effect on blood vessel inflammation. As well, the information from this study will be used to determine the number of patients to recruit in a future study.

This study will evaluate the effect of etanercept on 10 patients with rheumatoid arthritis at one rheumatology clinic in Montreal. The 10 patients will be recruited at the Montreal Rheumatology Institute (Institut de Rhumatologie de Montréal) and the images of the blood vessels taken at a medical imaging center will be analyzed by the Montreal Heart Institute.

To evaluate vascular inflammation subjects will undergo a PET scan (Positron Emission Tomography).

This study is a 16 week, single center, open label trial, to study the effect of etanercept on vascular inflammation of the ascending aorta and carotid arteries in patients with rheumatoid arthritis (RA).

Patients with active RA already receiving methotrexate for at least 3 months will receive etanercept for 16 weeks. Etanercept will be administered sub-cutaneously using the dose approved in the Canadian product monograph for RA (50 mg every week). Patients will continue methotrexate at a stable dose during the study unless a dose reduction or cessation is required as judged necessary by the study investigator. Positron Emission Tomography (PET) Scan will be performed at baseline and after16 weeks of study treatment with etanercept. At the end of the study, all PET Scan images will be analyzed in a blinded manner by the Montreal Heart Institute core laboratory.

Safety will be assessed using adverse events collection and laboratory hematology and chemistry analysis (screening and Week 4) and pregnancy test.

Etanercept in Rheumatoid Arthritis and Vascular Inflammation

Pilot Open-label Study of the Effect of Etanercept on Vascular Inflammation in Patients With Active Rheumatoid Arthritis

Change from baseline in target (atherosclerotic plaque) to background (blood) ratio (TBR) from the ascending aorta.

Change from baseline in the TBR from the mean of both carotid arteries

Change from baseline in swollen and tender joint count

Correlation between change from baseline in TBR from the ascending aorta and change from baseline in hsCRP

Correlation between change from baseline in TBR from the mean of both carotid arteries and change from baseline in hsCRP

Correlation between change from baseline in TBR from the ascending aorta at and change from baseline in swollen and tender joint count

Correlation between change from baseline in TBR from the carotid arteries and change from baseline in swollen and tender joint count

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Etanercept in Rheumatoid Arthritis and Vascular Inflammation	NCT02109289	Rheumatoid Arth... Vascular Inflam...	etanercept	18 Years - 80 Years	Innovaderm Research Inc.
Etanercept in Rheumatoid Arthritis and Vascular Inflammation	NCT02109289	Rheumatoid Arth... Vascular Inflam...	etanercept	18 Years - 80 Years	Innovaderm Research Inc.

Spots Global Cancer Trial Database for vascular inflammation